Innovative Approaches Needed to Advance Studies on Pediatric Kidney Diseases
Kidney News · 07.08.2026 · 18 (8) · 1-3
DOI: 10.62716/kn.003892026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney News, erschienen am 07.08.2026. Verfasst von Bridget M. Kuehn. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
I t can take 13 years after clinical trial results to show that a therapy is safe and effective in adults before the drugs are tested and approved for pediatric use (1)."It can feel really unfair if there are good treatments available for adults that are going to take 13 years before they reach the patients in front of you," explained Louise Oni, MBChB, MRCPCH, MA, PhD, professor of pediatric nephrology at the University College London Centre for Kidney and Bladder Health, UK.That long gap puts pediatric patients, their parents or caregivers, and their pediatric nephrologists in a bind as they determine whether to consider off-label use of medications.Oni said that it can be challenging to explain the limited data on safety and efficacy for pediatric patients to family members, and physicians often must extrapolate dosing from adult data."Sometimes there's shock, and sometimes they're so desperate for treatment that they would accept anything, but it puts a lot of pressure [on the clinician]," she said."Off-label use is dependent on which clinicians would be willing to take that responsibility and allow that treatment to be used."
Zitieren
APA
Kuehn, B. M. (2026). Innovative Approaches Needed to Advance Studies on Pediatric Kidney Diseases. Kidney News, 18(8), 1-3. https://doi.org/10.62716/kn.003892026
Vancouver
Kuehn BM. Innovative Approaches Needed to Advance Studies on Pediatric Kidney Diseases. Kidney News. 2026;18(8):1-3. doi:10.62716/kn.003892026
BibTeX
@article{Kuehn2026,
author = {Kuehn, Bridget M.},
title = {Innovative Approaches Needed to Advance Studies on Pediatric Kidney Diseases},
journal = {Kidney News},
year = {2026},
volume = {18},
number = {8},
pages = {1--3},
doi = {10.62716/kn.003892026}
}
EUVIMED